<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Resveratrol blocks Akt activation in angiotensin II- or EGF-stimulated vascular smooth muscle cells in a redox-independent manner</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Oxford University Press (OUP)</publisher>
				<availability status="unknown"><p>Copyright Oxford University Press (OUP)</p>
				</availability>
				<date type="published" when="2010-11-10">10 November 2010</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cornelia</forename><forename type="middle">E</forename><surname>Schreiner</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pharmacognosy</orgName>
								<orgName type="institution">University of Vienna</orgName>
								<address>
									<addrLine>Althanstraße 14</addrLine>
									<postCode>1090</postCode>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mario</forename><surname>Kumerz</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pharmacognosy</orgName>
								<orgName type="institution">University of Vienna</orgName>
								<address>
									<addrLine>Althanstraße 14</addrLine>
									<postCode>1090</postCode>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julia</forename><surname>Gesslbauer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pharmacognosy</orgName>
								<orgName type="institution">University of Vienna</orgName>
								<address>
									<addrLine>Althanstraße 14</addrLine>
									<postCode>1090</postCode>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><surname>Schachner</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pharmacognosy</orgName>
								<orgName type="institution">University of Vienna</orgName>
								<address>
									<addrLine>Althanstraße 14</addrLine>
									<postCode>1090</postCode>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Helge</forename><surname>Joa</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pharmacognosy</orgName>
								<orgName type="institution">University of Vienna</orgName>
								<address>
									<addrLine>Althanstraße 14</addrLine>
									<postCode>1090</postCode>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><surname>Erker</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Pharmaceutical/Medicinal Chemistry</orgName>
								<orgName type="institution">University of Vienna</orgName>
								<address>
									<addrLine>Althanstraße 14</addrLine>
									<postCode>1090</postCode>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Atanas</forename><forename type="middle">G</forename><surname>Atanasov</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pharmacognosy</orgName>
								<orgName type="institution">University of Vienna</orgName>
								<address>
									<addrLine>Althanstraße 14</addrLine>
									<postCode>1090</postCode>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elke</forename><forename type="middle">H</forename><surname>Heiss</surname></persName>
							<email>elke.heiss@univie.ac.at</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Pharmacognosy</orgName>
								<orgName type="institution">University of Vienna</orgName>
								<address>
									<addrLine>Althanstraße 14</addrLine>
									<postCode>1090</postCode>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Verena</forename><forename type="middle">M</forename><surname>Dirsch</surname></persName>
							<email>verena.dirsch@univie.ac.at</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Pharmacognosy</orgName>
								<orgName type="institution">University of Vienna</orgName>
								<address>
									<addrLine>Althanstraße 14</addrLine>
									<postCode>1090</postCode>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Resveratrol blocks Akt activation in angiotensin II- or EGF-stimulated vascular smooth muscle cells in a redox-independent manner</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Cardiovascular Research</title>
						<idno type="ISSN">0008-6363</idno>
						<idno type="eISSN">1755-3245</idno>
						<imprint>
							<publisher>Oxford University Press (OUP)</publisher>
							<biblScope unit="volume">90</biblScope>
							<biblScope unit="issue">1</biblScope>
							<biblScope unit="page" from="140" to="147"/>
							<date type="published" when="2010-11-10">10 November 2010</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1093/cvr/cvq355</idno>
					<idno type="PMID">21071431</idno>
					<idno type="PMCID">PMC3058730</idno>
					<ptr type="open-access" target="https://academic.oup.com/cardiovascres/article-pdf/90/1/140/17235451/cvq355.pdf" />
					<note type="submission">Received 17 May 2010; revised 22 October 2010; accepted 5 November 2010</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-13T23:51+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>Vascular smooth muscle cells † Angiotensin II † Epidermal growth factor † Redox-regulation</keywords>
			</textClass>
			<abstract>
				<p>Time for primary review: 43 days Aims Resveratrol (RV), an antioxidant, inhibits angiotensin II (Ang II)-induced hypertrophy and Ang II-or epidermal growth factor (EGF)-induced Akt phosphorylation in rat vascular smooth muscle cells (VSMCs). Both signalling pathways are reported to utilize reactive oxygen species (ROS). The aim of this study was to show whether RV reduces the ROS level in Ang II-or EGF-activated VSMCs and whether reduction of ROS causes the impeded signalling towards Akt in the presence of RV. Methods and results We show here that RV reduces intracellular ROS and extracellular H 2 O 2 release from VSMCs as measured using 2 ′ ,7 ′-dichlorodihydrofluorescein-diacetate and Amplex Red TM. Since NADPH oxidases (Nox) 1 and 4 are major ROS sources in VSMCs, we examined their need for Akt phosphorylation in response to Ang II or EGF. Experiments using the blocking peptide gp91ds-tat verified a role for Nox1 in Ang II signalling towards Akt, but excluded a role for Nox1 in the respective EGF signalling. A small interfering RNA-mediated knock-down of Nox4 showed that Nox4 was not required for Ang II-or EGF-induced Akt phosphorylation. Use of the flavoprotein inhibitor diphenyleneiodonium, N-acetyl-cysteine, and non-antioxidant RV derivatives revealed that the antioxidant capacity of RV is not required for the inhibition of Akt phosphorylation, in both rat and human VSMCs. Conclusion Thus, although RV acts as an antioxidant, the antihypertrophic response of RV in VSMCs and the signalling downstream of the EGF receptor towards Akt seem to be largely redox independent.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p>The small polyphenol resveratrol (RV), found in various plant-derived sources, including grapes, is considered to contribute to the beneficial effect of red wine in cardiovascular diseases. <ref type="bibr">1 -3</ref> Pharmacological activities of RV relevant for a putative cardio-and vasoprotective effect include the reduction of platelet aggregation, low-density lipoprotein oxidation, prostaglandin synthesis, and tumour necrosis factor-a-induced activation of endothelial cells, as well as the promotion of endothelial nitric oxide (NO) synthase expression and activity. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b2">3</ref> In addition, RV has been shown to inhibit growth-related signalling pathways in cardiac fibroblasts and to protect against ischaemia-reperfusion injury. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b2">3</ref> Previous work of our group has demonstrated an antihypertrophic action of RV in angiotensin II (Ang II)-activated vascular smooth muscle cells (VSMCs), which is mediated by a selective inhibition of Akt phosphorylation. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref> Angiotensin II is a potent vasoconstrictor, but is also involved in inflammatory processes, vascular oxidative stress, cell growth, and extracellular matrix deposition, promoting endothelial dysfunction and vascular remodelling. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref> In the vessel wall, VSMCs are the principal target cells of Ang II in which it promotes contraction contraction, cell growth (hypertrophy), migration, and increased extracellular matrix deposition via activation of the Ang II type 1 AT 1 receptor. <ref type="bibr" target="#b6">7</ref> In VSMCs, the cellular signalling pathways mediating hypertrophy are complex. Important steps are the activation of NAD(P)H oxidase, a major source of cellular reactive oxygen species (ROS), and the transactivation of the epidermal growth factor (EGF) receptor (EGF-R) in a ROS-and c-Src-dependent manner. <ref type="bibr">6 -9</ref> Downstream of the EGF-R, Akt and extracellular signal-regulated kinase (ERK) signalling pathways are activated. <ref type="bibr" target="#b8">9</ref> We have previously shown that RV does not interfere with the transactivation of the EGF-R in Ang II-activated VSMCs when inhibiting Akt phosphorylation. In accordance with this, EGF-induced Akt phosphorylation was also inhibited by RV in VSMCs. <ref type="bibr" target="#b4">5</ref> Thus, RV interferes with the signalling towards Akt downstream of the EGF-R in Ang II-or EGF-activated VSMCs. The exact mode of action of RV in VSMCs has remained elusive, although some data have suggested activation of the redox-sensitive proteintyrosine phosphatase (PTP) Shp2 (Src homology-2-containing proteintyrosine phosphatase-2) as a mechanism. <ref type="bibr" target="#b4">5</ref> Many activities of RV that are thought to contribute to its cardioand vasoprotective effect, including the activation of redox-sensitive PTPs, such as Shp2, may be explained by its antioxidant activity. <ref type="bibr" target="#b1">2</ref> ROS are involved in cell signaling, leading to cell growth and migration, activation of MMPs, altered function of many kinases and phosphatases, and activation of pro-inflammatory transcription factors. <ref type="bibr" target="#b9">10</ref> In addition, ROS oxidize low-density lipoprotein and may inactivate NO. <ref type="bibr" target="#b10">11</ref> In VSMCs, the most important source of ROS are the NAD(P)H oxidases Nox1 and Nox4. <ref type="bibr">12 -14</ref> Nox1 is highly expressed in proliferating VSMCs and is activated by a variety of growth factors, such as Ang II and platelet-derived growth factor, contributing to their activation of p38 mitogen-activated protein kinase and Akt. <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b15">16</ref> The function of Nox4, the only constitutively active NAD(P)H oxidase, is less clear. <ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b15">16</ref> In VSMCs, Nox4 was found within distinct subcellular locations, such as the nucleus or the endoplasmic reticulum, but also at focal adhesions where the transactivated EGF-R and phosphatidylinositol 3-kinase (PI3K) can be found after Ang II stimulation. <ref type="bibr">15 -18</ref> While Nox1 is known to be required for Ang II-induced EGF-R transactivation, little is known how the EGF-activated EGF-R induces ROS production <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20</ref> that may lead to PTP oxidation and signal transduction. <ref type="bibr" target="#b20">21</ref> The aim of this study, therefore, was to investigate the following: (i) whether RV reduces the ROS level in or H 2 O 2 released from Ang IIor EGF-activated VSMCs; (ii) whether Nox1 or Nox4 proteins, or ROS in general, are required for the phosphorylation of Akt downstream of the EGF-R; and thus (iii) whether RV may act directly or indirectly as an 'antioxidant' when inhibiting the phosphorylation of Akt.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">Reagents</head><p>Materials were obtained from the following suppliers: antibodies against phospho-Akt (Ser 473 ) and phospho-p38 were from Cell Signaling Technology, anti-tubulin antibody was obtained from Santa Cruz Biotechnology. Resveratrol, Ang II, diphenyleneiodonium (DPI) and N-acetyl-cysteine (NAC) were purchased from Sigma-Aldrich. Epidermal growth factor was obtained from Upstate. 2 ′ ,7 ′ -Dichlorodihydrofluorescein-diacetate (H 2 DCF-DA) and the Amplex Red TM reagent were from Molecular Probes/Invitrogen. The blocking peptide for Nox1 (Nox2 is not expressed in rat VSMCs; <ref type="bibr" target="#b21">22</ref> and own unpublished results), gp91ds-tat, was [H]-RKKRRQRRRCSTRIRRQL-NH 2 , and the control peptide used was [H]-RKKRRQRRRAGAGAGAGA-NH2, both from CASLO Laboratory ApS. All chemicals used for the synthesis of RV derivatives, unless otherwise stated, were analytical grade and obtained from Sigma-Aldrich Chemie GmbH (Schnelldorf, Germany), TCI Europe (Zwijndrecht, Belgium) and Apollo Scientific Limited (Bredbury, UK) and used without further purification.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">Cultivation of cells</head><p>The VSMCs were provided by Drs Kathy K. Griendling and Dan Sorescu (Emory University School of Medicine) and were obtained by three independent isolations from male Sprague-Dawley rat (200 -250 g, 5 -8 weeks old) thoracic aortas by enzymatic digestion as described previously. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b22">23</ref> Cells were grown in phenol red-free Dulbecco's modified Eagle's medium supplemented with 10% calf serum, 2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin (growth medium). For experiments, cells between passage 7 and 15 were used at 70% confluence. Prior to all growth factor stimulation experiments, cells were starved for 24 h in Dulbecco's modified Eagle's medium containing 0.1% calf serum supplemented with 2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin (starve medium).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">SDS-PAGE and western blotting</head><p>For experiments, cells were grown in 60 mm dishes and serum starved overnight in starve medium, then treated with Ang II (100 nM) or EGF (100 ng/mL) for the indicated time. Resveratrol (50 mM), vehicle control [dimethyl sulfoxide (DMSO) 0.1%], gp91ds-tat or the respective control peptide (100 mM) were added 30 min before stimulation. The VSMCs were pretreated with DPI (10 mM) for 1 h and NAC (10 mM) for 2 h before stimulation. Cells were then suspended in lysis buffer (50 mM HEPES, 50 mM NaCl, 5 mM EDTA, 10 mM sodium pyrophosphate, 50 mM NaF, 1 mM sodium orthovanadate, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride and 1× complete protease inhibitor cocktail). Western blot analysis was performed as described previously. <ref type="bibr" target="#b3">4</ref> Proteins of interest were visualized by the use of specific antibodies, an ECL system and a CCD camera (Fuji LAS 3000). Densitometric evaluation was performed by employing the AIDA image analyser 4.06 software (Raytest).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">Measurement of intracellular ROS</head><p>For detection of the intracellular total ROS level, cells were grown in six-well plates and treated as indicated. Quiescent cells were washed once with pre-warmed HEPES buffered saline solution and incubated at 378C for 30 min with 20 mM H 2 DCF-DA before stimulation with EGF (100 ng/mL) or Ang II (100 nM) for the indicated periods of time. Cells were then immediately analysed by flow cytometry (FACSCalibur, BD Bioscience). The mean fluorescence of 10 000 analysed cells (corrected for autofluorescence) was detected and used as a measurement for total ROS.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5">Determination of extracellular H 2 O 2 level</head><p>The VSMCs were grown in 24-well plates and serum starved for 24 h. Cells were washed once with prewarmed phosphate-buffered saline, then krebs ringer phosphate glucose buffer containing the Amplex Red TM reagent was applied to the cells. Plates were incubated for 15 min at 378C before VSMCs were stimulated as indicated. Resorufin, the fluorescent product, was measured in triplicate by a fluorescence multi-well plate reader with an excitation wavelength of 535 nm and an emission wavelength of 590 nm (Genios Pro, Tecan, Switzerland).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6">Transfection with small interfering RNA and quantitative real-time PCR</head><p>Five hours after seeding, VSMCs were transfected with small interfering RNA (siRNA; siNox4 from ThermoFisher Scientific, 50 nM; or scrambled siRNA control from Invitrogen) using Oligofectamine (Invitrogen) and Opti-MEM 1 (Gibco). For Nox4, the sequences used were sense 5 ′ -ACUGAGGUACAGCUGGAUGUU-3 ′ , and antisense 5 ′ -CAUCCAG CUGUACCUCAGUUU-3 ′ . Experiments were performed 72 h after siRNA transfection. The knock-down efficiency was verified by quantitative real-time PCR (qPCR). For this, mRNA was isolated using the pegGOLD total RNA Kit (Peqlab), and reverse transcription was performed using Superscript TM First-Strand Synthesis System (Invitrogen) according to the manufacturer's protocol. PCR was carried out with a LightCycler TM LC480 SYBR Green I Master reagent (Roche Diagnostics) and the LightCycler TM LC480 (Roche Diagnostics) system.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.7">Synthesis of RV derivatives</head><p>Methylated resveratrol derivatives were synthesized according to the literature. <ref type="bibr" target="#b23">24</ref> Both 1 H and 13 C nuclear magnetic resonance spectra were recorded on a Bruker Advance DPx200 (200 and 50 MHz). Mass spectra (MS) were obtained by a Shimadzu (GC-17A; MS-QP5050A) spectrometer.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.8">Statistical analysis</head><p>Results are expressed as means + SEM. Statistical analysis was performed by ANOVA followed by Dunnett's multiple comparison test or by onesample t-test using GraphPad PRISM, version 4.0 (GraphPad Software, San Diego, CA, USA). Differences with P , 0.05 were considered significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">Resveratrol reduces intracellular total ROS level and H 2 O 2 release from VSMCs</head><p>First, we asked whether RV reduces intracellular total ROS level and/or H 2 O 2 released from VSMCs and thereby leads to inhibition of Akt phosphorylation as described earlier. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref> Since NAD(P)H <ref type="figure">Figure 1</ref> Resveratrol (RV) diminishes intracellular reactive oxygen species (ROS) level and attenuates both basal and angiotensin II (Ang II)-or epidermal growth factor (EGF)-induced extracellular H 2 O 2 . Quiescent vascular smooth muscle cells (VSMCs) were pre-incubated with dichlorodihydrofluorescein-diacetate (H 2 DCF-DA; 20 mM, 15 min) and then incubated with 50 mM RV or vehicle control for 30 min or 10 mM diphenyleneiodonium (DPI) for 1 h and finally stimulated with 100 nM Ang II for 15 min (A) or 100 ng/mL EGF for 10 min (B). ROS production (equivalent to the amount of formed DCF) was analysed by flow cytometry. The average fluorescence signal obtained in the presence of Ang II or EGF was set to 100% (**P , 0.01; one-way ANOVA vs. Ang II or EGF treatment, n ¼ 3). Serum-starved VSMCs were stimulated in Amplex Red TM buffer with Ang II (100 nM; C) or EGF (100 ng/mL; D) for 5 -15 min after pre-incubation with RV (50 mM) or vehicle control for 30 min. H 2 O 2 production was quantified by fluorescence measurement. Absolute values were correlated to catalase-treated cells used as a negative control. oxidases play a pivotal role in VSMC-derived ROS production, DPI, an unspecific inhibitor of flavin-containing enzymes including NAD(P)H oxidases, <ref type="bibr" target="#b24">25</ref> was used as positive control. For detection of intracellular ROS, we loaded VSMCs with 20 mM H 2 DCF-DA. Angiotensin II (100 nM) was able to induce ROS production twofold compared with the vehicle control. Resveratrol (50 mM) and DPI (10 mM) pre-treatment reduced this ROS production almost to the basal level ( <ref type="figure">Figure 1A)</ref>. In contrast, treatment of cells with 100 ng/mL EGF, a concentration that readily induced Akt phosphorylation, did not lead to a significant activation of intracellular ROS production in comparison with the vehicle control. Resveratrol and DPI, however, were able to inhibit basal intracellular ROS level by about 50% ( <ref type="figure">Figure 1B)</ref>, verifying a strong ROS reducing activity for both compounds. Activation of the EGF-R has been reported to lead to increased extracellular H 2 O 2 levels in A431 cells. <ref type="bibr" target="#b18">19</ref> Therefore, we also measured extracellular H 2 O 2 level using Amplex Red TM . Both Ang II and EGF were able to induce the extracellular release of H 2 O 2 in a time-dependent manner ( <ref type="figure">Figure 1C and D)</ref>. Whereas EGF treatment led to a continuous accumulation of H 2 O 2 , which was highest after 15 min (20% above basal level), H 2 O 2 production after Ang II stimulation peaked at 10 min (15% above basal level). Resveratrol reduced Ang II-and EGF-induced H 2 O 2 but also basal levels far below control values ( <ref type="figure">Figure 1C and D)</ref>. These findings demonstrate that RV blocks both H 2 O 2 detected in the extracellular environment and intracellular total ROS produced in VSMCs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">A Nox4 knock-down does not influence the phosphorylation of Akt in Ang II-or EGF-activated VSMCs</head><p>To investigate whether Nox4 is important for the EGF-or Ang II-induced signalling towards Akt in our cell system, Nox4 was knocked down by siRNA. After 72 h, Nox4 mRNA level was analysed by qPCR. The siRNA reduced the Nox4 mRNA level to 15% compared with scrambled control, whereas the mRNA level of Nox1 was unchanged <ref type="figure" target="#fig_1">(Figure 2A and B)</ref>. As expected, knock-down of Nox4 had no impact on the phosphorylation of Akt after Ang II (100 nM, 10 min) stimulation. Moreover, the inhibitory effect of RV on Akt phosphorylation remained unaffected ( <ref type="figure" target="#fig_1">Figure 2C)</ref>. Interestingly, the EGF-induced Akt phosphorylation and the inhibitory effect of RV also remained unaltered in Nox4 knock-down cells ( <ref type="figure" target="#fig_1">Figure 2D)</ref>. Thus, Nox4 seems not to be involved in Ang II-or EGF-mediated phosphorylation of Akt, and therefore Nox4-derived ROS are not a potential target of RV. Data were normalized by setting scrambled control to 100% (***P , 0.001; n ¼ 3). Serum-deprived Nox4 siRNA-treated cells (50 nM, 72 h) were pre-treated with RV (50 mM, 30 min) or vehicle control followed by stimulation with 100 nM Ang II for 10 min (C ) or 100 ng/mL EGF for 5 min (D). Akt phosphorylation and tubulin (tub, serving as a loading control) were detected by western blot analysis. One representative blot out of three, which were densitometrically analysed, is shown. The graphs represent the mean densitometric values + SEM of three independent experiments. Akt phosphorylation in response to Ang II or EGF of scrambled control was set to 100% (*P , 0.05, **P , 0.01; one-way ANOVA, n ¼ 3).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 3 Inhibition of Nox1 blunts phosphorylation of Akt and</head><p>p38 induced by Ang II but does not alter EGF-induced Akt and p38 phosphorylation. Quiescent VSMCs were pre-treated with 100 mM of the gp91ds-tat blocking peptide (gp91ds), 50 mM RV or vehicle control for 30 min, and were then stimulated with 100 nM Ang II for 10 min (A and B) or 100 ng/mL EGF (C and D) for 5 min. Akt (A and C) and p38 phosphorylation (B and D) as well as tubulin (tub, as loading control) were detected by western blot analysis. One representative blot out of three, which were densitometrically analysed, is shown. The graphs depict the mean densitometric values + SEM of three independent experiments. Signals obtained in response to Ang II or EGF were set to 100% (*P , 0.05, **P , 0.01; n.s., not significant; one-way ANOVA vs. Ang II or EGF treatment, n ¼ 3).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">Down-regulation of Nox1 inhibits Akt phosphorylation in response to Ang II but not EGF stimulation</head><p>In Ang II-activated VSMCs, Nox1 has been shown to be the major ROS-producing component necessary for the transactivation of the EGF-R, leading finally to Akt activation. <ref type="bibr" target="#b15">16</ref> To the best of our knowledge, however, it is unknown whether EGF utilizes Nox1 to transduce its growth signal, although in transactivated settings prolonged Nox1 activation seems to need Rac1 activation via PI3K downstream of the EGF-R. <ref type="bibr" target="#b15">16</ref> To inhibit Nox1 we employed 100 mM of the blocking peptide gp91ds-tat that prevents assembly of the Nox protein with cofactors <ref type="bibr" target="#b11">12</ref> or a control peptide. As expected, gp91ds-tat pretreatment led to an inhibition of Ang II-mediated Akt phosphorylation ( <ref type="figure">Figure 3A)</ref>. In contrast to RV, gp91ds-tat also inhibited the phosphorylation of p38, a known redox-sensitive kinase, by more than 50% ( <ref type="figure">Figure 3B)</ref>. In EGF-activated VSMCs, gp91ds-tat, in contrast to RV, had no effect on Akt phosphorylation ( <ref type="figure">Figure 3C)</ref>. A putative effect of gp91ds-tat on p38 phosphorylation did not reach significance ( <ref type="figure">Figure 3D)</ref>. The unspecific control peptide used had no influence on Akt or p38 phosphorylation in response to either stimulus (data not shown). These data show that Nox1 is important for Ang II-but not for EGF-mediated phosphorylation of Akt and p38. Inhibition of Nox1 is not able to mimic the effect of RV in our setting, and thus renders Nox1-derived ROS an unlikely target of RV.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4">Both DPI and NAC inhibit Akt phosphorylation upon Ang II but not EGF stimulation</head><p>To further clarify the general dependency of EGF-and Ang II-induced signalling towards Akt and p38 on ROS we applied the Nox/flavoprotein inhibitor DPI (10 mM) and the precursor of glutathione, NAC (10 mM). We found that Ang II-induced phosphorylation of Akt was blocked by NAC as effectively as by RV, while DPI was less effective ( <ref type="figure" target="#fig_3">Figure 4A)</ref>. In contrast to RV, which had no effect on the phosphorylation of p38 after Ang II stimulation, NAC and DPI were able to block the phosphorylation to basal levels ( <ref type="figure" target="#fig_3">Figure 4B)</ref>. Phosphorylation of Akt upon EGF stimulation was inhibited effectively only by RV; NAC and DPI had no consistent inhibitory effect ( <ref type="figure" target="#fig_3">Figure 4C</ref>). Resveratrol, NAC or DPI did not inhibit p38 phosphorylation in response to EGF stimulation ( <ref type="figure" target="#fig_3">Figure 4D</ref>). These data indicate that Ang II, as described, utilizes ROS for its signal transduction towards Akt and p38, but EGF does not. Moreover, RV seems not to require its antioxidant activity to inhibit Akt phosphorylation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5">A non-antioxidant RV derivative inhibits Ang II and EGF-mediated Akt phosphorylation</head><p>To confirm that RV, although redox-active, does not act as an antioxidant when inhibiting Akt phosphorylation we employed the following two non-antioxidant derivatives of RV: trans-3,5,4 ′ -trimethoxystilbene (RV-3M) with all three hydroxyl groups methylated ( <ref type="figure" target="#fig_2">Figure 5A</ref>) and thus blunted redox activity, <ref type="bibr" target="#b26">26</ref> and trans-3,5-dihydroxy-4 ′ -methoxystilbene (RV-1M), methylated at the 4 ′ -OH group only  Akt and p38. Serum-deprived cells were pre-treated with 50 mM RV or vehicle control for 30 min, 10 mM DPI for 1 h or 10 mM NAC for 2 h, and then stimulated with 100 nM Ang II for 10 min (A and B), or 100 ng/mL EGF for 5 min (C and D). Lysates were subjected to western blot analysis using antibodies against pAkt (A and C), pp38 (B and D) and tubulin (tub). Representative blots out of three are shown. The graphs depict the mean + SEM of the densitometric analyses. Signals obtained in response to Ang II or EGF were set to 100% (*P , 0.05, **P , 0.01; n.s., not significant; one-way ANOVA vs. Ang II or EGF treatment, n ¼ 3).</p><p>( <ref type="figure" target="#fig_2">Figure 5B)</ref>. Mono-methylation at the 4 ′ -OH group renders RV largely redox inactive, since Queiroz et al. have recently shown that the prime antioxidant pharmacophore of RV is 4 ′ -hydroxystilbene, <ref type="bibr" target="#b27">27</ref> a finding that is also supported by others <ref type="bibr" target="#b26">26</ref> and confirmed by our synthesized derivatives in vitro (see Supplementary material online, <ref type="figure">Figure  S1</ref>). To test their redox activity in the presence of cells we used Amplex Red TM to detect extracellular H 2 O 2 in the presence of RV or its derivatives, RV-3M and RV-1M. As expected, neither of the two derivatives was found to reduce extracellularly detected H 2 O 2 significantly after stimulation of VSMCs with Ang II ( <ref type="figure">Figure 6A</ref>). Using Akt phosphorylation as read-out, RV-3M inhibited neither Ang II-nor EGF-induced Akt phosphorylation. Most interestingly, however, the derivative RV-1M, despite its lack of influence on H 2 O 2 , reduced phosphorylation of Akt in response to Ang II treatment by over 50%, which was comparable to RV-mediated inhibition. The EGF-induced phosphorylation of Akt was inhibited equally well by RV-1M compared with RV ( <ref type="figure">Figure 6B and C)</ref>. These data clearly show that RV inhibits Akt phosphorylation by a mechanism that is not related to its antioxidant activity in both Ang II-and EGFstimulated VSMCs. In contrast, the 3-and 5-OH groups of RV seem to be critically involved in mediating Akt inhibition. A consistent picture of redox-independent inhibition of Akt phosphorylation by RV and RV-1M was observed in human primary aortic smooth muscle cells (see Supplementary material online, <ref type="figure" target="#fig_1">Figure S2</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head><p>We show here for the first time that although RV reduces total intracellular ROS level and extracellular H 2 O 2 release, its antioxidant activity is not required for the inhibition of Akt phosphorylation in Ang II-or EGF-activated VSMCs. Moreover, we show that in VSMCs, EGF leads to an increase of extracellular H 2 O 2 level but not of intracellular ROS production. This H 2 O 2 seems not to play a major role for the signal transduction towards Akt and p38. Furthermore, we confirm that the Ang II-induced signalling pathways towards Akt and p38 require Nox1, and clearly show that Nox4 is not required for Ang II-or EGF-induced Akt activation.</p><p>Many pharmacological effects of RV are believed to be related to its antioxidant activity. In the field of cardiovascular diseases, Opie &amp; Lecour recently summarized several of the RV effects that could be linked to an antioxidant action, including inhibition of low-density lipoprotein oxidation, inhibition of prostaglandin synthesis, downregulation of intercellular adhesion molecule-1 and nuclear factor-kB, reduction of platelet activation and inhibition of Ang II-induced cardiomyocyte hypertrophy, and they speculated that even more RV effects might be redox related, although not proven yet. <ref type="bibr" target="#b1">2</ref> Especially the report showing that RV inhibits Ang II-induced cardiomyocyte hypertrophy by its antioxidant activity may be of interest in our context. The authors show that RV (1-100 mM) inhibits Ang II-induced [ 3 H]leucine incorporation as a measure for hypertrophy, beta-myosin heavy chain promoter activity, intracellular ROS level and ERK phosphorylation (although not examining other kinases) in cardiomyocytes. To link the antioxidant activity to the antihypertrophic effect of RV, they show that RV and the antioxidant NAC inhibit Ang II-or H 2 O 2 -induced [ 3 H]leucine incorporation in cardiomyocytes comparably. <ref type="bibr" target="#b28">28</ref> In some <ref type="figure">Figure 6</ref> Non-antioxidant trans-3,5-dihydroxy-4 ′ -methoxystilbene (RV-1M) inhibits phosphorylation of Akt after Ang II and EGF stimulation. (A) Starved VSMCs were stimulated in Amplex Red TM buffer with Ang II (100 nM) for 10 min after pre-incubation with RV or RV derivatives (RV, RV-3M, RV-1M; all 50 mM), or vehicle control for 30 min. H 2 O 2 production was quantified by fluorescence measurement. The graph shows the relative extracellular H 2 O 2 production (**P , 0.01; one-way ANOVA vs. Ang II or EGF treatment, n ¼ 3). (B and C). Serum-deprived cells were pre-treated with RV or RV derivatives, RV-3M or RV-1M, for 30 min (50 mM), followed by stimulation with 100 nM Ang II for 10 min (B), or 100 ng/mL EGF for 5 min (C ). Protein levels were detected by western blot using antibodies against pAkt and tubulin. One representative blot out of three per stimulation is shown. Graphs show the mean + SEM of the densitometric signals; Ang II or EGF stimulation is set to 100% (**P , 0.01; one-way ANOVA vs. Ang II or EGF treatment, n ¼ 3). parts, the above report is in agreement with this and previous studies of our group, although we used VSMCs instead of cardiomyocytes; we found an inhibition of Ang II-induced hypertrophy measured by [ 3 H]leucine incorporation <ref type="bibr" target="#b3">4</ref> and now also ROS production by RV. Next to a minor effect on ERK phosphorylation, we found a strong inhibition of the PI3K -Akt pathway leading more downstream to an effective inhibition of p70 S6 kinase important for cellular hypertrophy. <ref type="bibr" target="#b3">4</ref> Here we show, however, that inhibition of ROS and Akt phosphorylation are two parallel events mediated by RV that could not be causally linked in our system.</p><p>Our data also imply that the transduction of the signal induced by EGF in VSMCs is less redox dependent than that of Ang II, at least towards Akt and p38. Indeed, data regarding the ROS production of the EGF-activated (not transactivated) EGF-R and their importance for subsequent signal transduction are limited. The first report showing an intracellular increase in H 2 O 2 production in response to EGF used epithelial A431 cells and concentrations of EGF as high as 500 ng/mL for stimulation. <ref type="bibr" target="#b29">29</ref> Halvey et al., <ref type="bibr" target="#b19">20</ref> also detecting an increase of intracellular ROS after EGF stimulation in HaCaT cells, still used 200 ng/mL EGF. In agreement with our data, DeYulia et al. <ref type="bibr" target="#b18">19</ref> showed in 293T cells transiently transfected with EGF-R that the addition of EGF (50 ng/mL) results in elevated extracellular H 2 O 2 . They even found that solely the receptor -ligand interaction using isolated proteins was sufficient to produce H 2 O 2 . The exact mechanism by which ROS is produced, however, remained elusive. Regarding the ROS source that might be used by the EGF-R to transduce the EGF signal, Chen et al. proposed Nox4 that is localized at the endoplasmic reticulum and is critical for the regulation of PTP1B. Using human aortic endothelial cells (HAECs), and for transfection studies COS-7 cells, they suggest that Nox4-mediated oxidation and inactivation of PTP1B in the endoplasmic reticulum serves as a regulatory switch for EGF-R trafficking that terminates the EGF signal. <ref type="bibr" target="#b30">30</ref> Moreover, both the activated EGF-R as well as Nox4 were shown to be localized at focal adhesions in VSMCs. <ref type="bibr" target="#b31">31</ref> Knocking down Nox4 in our system, however, had no influence on EGF-as well as Ang II-induced Akt phosphorylation, which excludes Nox4 as essential mediator of signal transduction towards Akt downstream of the AT 1 -and EGF-R as well as a potential target of RV.</p><p>While the impact of Nox4-derived ROS for a variety of physiological processes, including cell growth, death, and differentiation is not completely understood, the role of Nox1 in VSMC is much better defined. <ref type="bibr" target="#b15">16</ref> Nox1-derived ROS was shown to regulate smooth muscle cell growth (hypertrophy and hyperplasia) and migration. The best-studied mechanism by which Nox1 is activated is that via the AT 1 receptor by Ang II, including activation of phospholipase C and subsequently protein kinase C that phosphorylates p47phox, a regulatory subunit of Nox1. Transactivation of the EGF-R leads to a PI3K-dependent activation of Rac1 that is required for continued activation of Nox1 by Ang II. <ref type="bibr" target="#b15">16</ref> Our data presented here again verify this model; the blocking peptide gp91ds-tat effectively inhibited the Ang II-induced signalling towards Akt and p38. In contrast, EGF-mediated phosphorylation of Akt and p38 was not significantly altered. We, therefore, excluded a Nox1-dependent mechanism activating Akt or p38 downstream of the EGF-R in our cells.</p><p>Several reports suggest an influence of RV on NAD(P)H oxidases in non-phagocytic cells. <ref type="bibr">32 -34</ref> In our experimental set-up, however, neither knock-down of Nox4 nor inhibition of Nox1 assembly could mimic the RV effect. In addition, previous studies showed that RV was unable to inhibit the transactivation of the EGF-R in Ang II-activated VSMCs, 5 a process highly regulated by Nox1. Nevertheless, it remains conceivable that RV contributes to the inhibition of Nox1-derived ROS production by the inhibition of PI3K-dependent Rac1 at later time points.</p><p>The strongest argument against a redox-dependent mechanism of the inhibition by RV of Ang II-or EGF-induced Akt activation came from RV derivatives that were not acting as antioxidants but were highly effective in inhibiting Akt phosphorylation ( <ref type="figure">Figure 6</ref>). Most interestingly, we found that the hydroxyl groups in the 3-and 5-positions are sufficient to block Ang II-or EGF-induced Akt phosphorylation. Although not detected, we cannot completely exclude the possibility that small or local rises in intracellular H 2 O 2 are quenched by these remaining two hydroxyl groups.</p><p>In summary, we could verify that Nox1 but not Nox4 is important for the Ang II-induced activation of Akt and p38 in VSMCs. The signalling triggered by EGF downstream of the EGF-R towards Akt and p38 phosphorylation seems to occur independently of Nox1, Nox4 or in general of ROS. Most interestingly, we showed that RV, although reducing intracellular ROS and extracellular H 2 O 2 levels in VSMCs, does not use an antioxidant mechanism to inhibit Akt phosphorylation in Ang II-or EGF-activated VSMCs.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>Graphs show the relative extracellular H 2 O 2 production expressed as a percentage of vehicle-treated control cells (open square, vehicle-treated cells; filled squares, RV-treated cells; ***P , 0.001; t-test, n ¼ 4).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc>Ang II-and EGF-induced Akt phosphorylation and its inhibition by RV occur independent of Nox4. Knock-down of Nox4 was achieved by treating cells with 50 nM small interfering RNA (siRNA) against Nox4 or 50 nM scrambled control siRNA for 72 h. The mRNA was isolated, and expression of Nox4 and Nox1 detected by qPCR. Graphs (A and B) show mean + SEM of Nox4 mRNA (A) or Nox1 mRNA (B) level relating to 18S mRNA.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 5</head><label>5</label><figDesc>Non-antioxidant derivatives of RV, trans-3,5,4 ′ -trimethoxystilbene (RV-3M; A), and trans-3,5-dihydroxy-4 ′ -methoxystilbene (RV-1M; B).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4</head><label>4</label><figDesc>DPI and NAC inhibit Ang II-induced phosphorylation of</figDesc></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p>The authors would like to express their gratitude to H. Beres, B. Gindl and R. Leitner for expert technical assistance. We also wish to thank Drs Kathy K. Griendling and Dan Sorescu (Emory University School of Medicine) for providing rat VSMCs as well as for useful advice and fruitful discussions.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary material</head><p>Supplementary material is available at Cardiovascular Research online.</p><p>Conflict of interest: none declared.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p>The work was supported by the Austrian Science Fund (FWF) [grant number P18982-B17 to V.M.D.]. Funding to pay the Open Access publication charge was provided by the Austrian Science Fund (FWF).</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Modulation of endothelial nitric oxide by plant-derived products</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christoph</forename><forename type="middle">A</forename><surname>Schmitt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Verena</forename><forename type="middle">M</forename><surname>Dirsch</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.niox.2009.05.006</idno>
		<idno type="PMID">19497380</idno>
	</analytic>
	<monogr>
		<title level="j">Nitric Oxide</title>
		<title level="j" type="abbrev">Nitric Oxide</title>
		<idno type="ISSN">1089-8603</idno>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="77" to="91" />
			<date type="published" when="2009-09" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The red wine hypothesis: from concepts to protective signalling molecules</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">H</forename><surname>Opie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lecour</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehm149</idno>
		<idno type="PMID">17561496</idno>
		<ptr type="open-access" target="https://academic.oup.com/eurheartj/article-pdf/28/14/1683/9628834/ehm149.pdf" />
	</analytic>
	<monogr>
		<title level="j">European Heart Journal</title>
		<title level="j" type="abbrev">European Heart Journal</title>
		<idno type="ISSN">0195-668X</idno>
		<idno type="ISSNe">1522-9645</idno>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1683" to="1693" />
			<date type="published" when="2007-03-06" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Cardioprotective actions of grape polyphenols</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wayne</forename><forename type="middle">R</forename><surname>Leifert</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mahinda</forename><forename type="middle">Y</forename><surname>Abeywardena</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.nutres.2008.08.007</idno>
		<idno type="PMID">19083481</idno>
	</analytic>
	<monogr>
		<title level="j">Nutrition Research</title>
		<title level="j" type="abbrev">Nutrition Research</title>
		<idno type="ISSN">0271-5317</idno>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="729" to="737" />
			<date type="published" when="2008-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Resveratrol Suppresses Angiotensin II-Induced Akt/Protein Kinase B and p70 S6 Kinase Phosphorylation and Subsequent Hypertrophy in Rat Aortic Smooth Muscle Cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><forename type="middle">G</forename><surname>Haider</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Sorescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">K</forename><surname>Griendling</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Vollmar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">M</forename><surname>Dirsch</surname></persName>
		</author>
		<idno type="DOI">10.1124/mol.62.4.772</idno>
		<idno type="PMID">12237323</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/3b75/be5ee7ee151314225d55b9b6e0947cedafc5.pdf" />
	</analytic>
	<monogr>
		<title level="j">Molecular Pharmacology</title>
		<idno type="ISSN">0026-895X</idno>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="772" to="777" />
			<date type="published" when="2002-10-01" />
			<publisher>American Society for Pharmacology &amp; Experimental Therapeutics (ASPET)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Resveratrol inhibits angiotensin II- and EGF-mediated Akt activation - role of Gab1 and Shp2</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><forename type="middle">G</forename><surname>Haider</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">U</forename><surname>Roos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">I</forename><surname>Kontaridis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">G</forename><surname>Neel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Sorescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">K</forename><surname>Griendling</surname></persName>
		</author>
		<idno type="DOI">10.1124/mol.104.005421</idno>
		<idno type="PMID">15849355</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/4ec2/6021880f8f0671dcadd8ec9d030366fe1564.pdf" />
	</analytic>
	<monogr>
		<title level="j">Molecular Pharmacology</title>
		<title level="j" type="abbrev">Molecular Pharmacology</title>
		<idno type="ISSN">0026-895X</idno>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="41" to="48" />
			<date type="published" when="2005-04-22" />
			<publisher>American Society for Pharmacology &amp; Experimental Therapeutics (ASPET)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Angiotensin-Converting Enzyme and Vascular Remodeling</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sylvia</forename><surname>Heeneman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Judith</forename><forename type="middle">C</forename><surname>Sluimer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mat</forename><forename type="middle">J A P</forename><surname>Daemen</surname></persName>
		</author>
		<idno type="DOI">10.1161/circresaha.107.148338</idno>
		<idno type="PMID">17761934</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.107.148338" />
	</analytic>
	<monogr>
		<title level="j">Circulation Research</title>
		<title level="j" type="abbrev">Circulation Research</title>
		<idno type="ISSN">0009-7330</idno>
		<idno type="ISSNe">1524-4571</idno>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="441" to="454" />
			<date type="published" when="2007-08-31" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Puja</forename><forename type="middle">K</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kathy</forename><forename type="middle">K</forename><surname>Griendling</surname></persName>
		</author>
		<idno type="DOI">10.1152/ajpcell.00287.2006</idno>
		<idno type="PMID">16870827</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/1d11/59d9da3a7e6ec77158a8dd556df551735953.pdf" />
	</analytic>
	<monogr>
		<title level="j">American Journal of Physiology-Cell Physiology</title>
		<title level="j" type="abbrev">American Journal of Physiology-Cell Physiology</title>
		<idno type="ISSN">0363-6143</idno>
		<idno type="ISSNe">1522-1563</idno>
		<imprint>
			<biblScope unit="volume">292</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="C82" to="C97" />
			<date type="published" when="2007-01" />
			<publisher>American Physiological Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Epidermal Growth Factor Receptor Transactivation by Angiotensin II Requires Reactive Oxygen Species in Vascular Smooth Muscle Cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ushio-Fukai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">K</forename><surname>Griendling</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">L</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Hilenski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Halleran</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">W</forename><surname>Alexander</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.atv.21.4.489</idno>
		<idno type="PMID">11304462</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/01.ATV.21.4.489" />
	</analytic>
	<monogr>
		<title level="j">Arteriosclerosis, Thrombosis, and Vascular Biology</title>
		<title level="j" type="abbrev">Arteriosclerosis, Thrombosis, and Vascular Biology</title>
		<idno type="ISSN">1079-5642</idno>
		<idno type="ISSNe">1524-4636</idno>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="489" to="495" />
			<date type="published" when="2001-04-01" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Angiotensin II signal transduction through the AT1receptor: novel insights into mechanisms and pathophysiology</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sadaharu</forename><surname>Higuchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Haruhiko</forename><surname>Ohtsu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroyuki</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Heigoro</forename><surname>Shirai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gerald</forename><forename type="middle">D</forename><surname>Frank</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Satoru</forename><surname>Eguchi</surname></persName>
		</author>
		<idno type="DOI">10.1042/cs20060342</idno>
		<idno type="PMID">17346243</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/7b81/e8e918f508a1ce01a653bbb0713377ebd4fe.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Science</title>
		<title level="j" type="abbrev">Clin. Sci.</title>
		<idno type="ISSN">0143-5221</idno>
		<idno type="ISSNe">1470-8736</idno>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="417" to="428" />
			<date type="published" when="2007-04-01" />
			<publisher>Portland Press Ltd.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Redox signaling in hypertension</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">M</forename><surname>Paravicini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">M</forename><surname>Touyz</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cardiores.2006.05.001</idno>
		<idno type="PMID">16765337</idno>
		<ptr type="open-access" target="https://academic.oup.com/cardiovascres/article-pdf/71/2/247/774413/71-2-247.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cardiovascular Research</title>
		<title level="j" type="abbrev">Cardiovascular Research</title>
		<idno type="ISSN">0008-6363</idno>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="247" to="258" />
			<date type="published" when="2006-07-15" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Beyond LDL oxidation: ROS in vascular signal transduction</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">R</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F</forename><surname>Keaney</surname><genName>Jr</genName></persName>
		</author>
		<idno type="DOI">10.1016/s0891-5849(03)00239-9</idno>
		<idno type="PMID">12853068</idno>
	</analytic>
	<monogr>
		<title level="j">Free Radical Biology and Medicine</title>
		<title level="j" type="abbrev">Free Radical Biology and Medicine</title>
		<idno type="ISSN">0891-5849</idno>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="117" to="132" />
			<date type="published" when="2003-07-15" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Karen</forename><surname>Bedard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Karl-Heinz</forename><surname>Krause</surname></persName>
		</author>
		<idno type="DOI">10.1152/physrev.00044.2005</idno>
		<idno type="PMID">17237347</idno>
		<ptr type="open-access" target="http://physrev.physiology.org/cgi/reprint/87/1/245.pdf" />
	</analytic>
	<monogr>
		<title level="j">Physiological Reviews</title>
		<title level="j" type="abbrev">Physiological Reviews</title>
		<idno type="ISSN">0031-9333</idno>
		<idno type="ISSNe">1522-1210</idno>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="245" to="313" />
			<date type="published" when="2007-01" />
			<publisher>American Physiological Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Selective targeting of NADPH oxidase for cardiovascular protection</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alison</forename><surname>Cave</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.coph.2008.10.001</idno>
		<idno type="PMID">18973829</idno>
	</analytic>
	<monogr>
		<title level="j">Current Opinion in Pharmacology</title>
		<title level="j" type="abbrev">Current Opinion in Pharmacology</title>
		<idno type="ISSN">1471-4892</idno>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="208" to="213" />
			<date type="published" when="2009-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hideki</forename><surname>Sumimoto</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1742-4658.2008.06488.x</idno>
		<idno type="PMID">18513324</idno>
	</analytic>
	<monogr>
		<title level="j">FEBS Journal</title>
		<idno type="ISSN">1742-464X</idno>
		<imprint>
			<biblScope unit="volume">275</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="3249" to="3277" />
			<date type="published" when="2008-06-28" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Composition and Functions of Vascular Nicotinamide Adenine Dinucleotide Phosphate Oxidases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ralf</forename><forename type="middle">P</forename><surname>Brandes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Katrin</forename><surname>Schröder</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tcm.2007.11.001</idno>
		<idno type="PMID">18206804</idno>
	</analytic>
	<monogr>
		<title level="j">Trends in Cardiovascular Medicine</title>
		<title level="j" type="abbrev">Trends in Cardiovascular Medicine</title>
		<idno type="ISSN">1050-1738</idno>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="15" to="19" />
			<date type="published" when="2008-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Nox proteins in signal transduction</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">I</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kathy</forename><forename type="middle">K</forename><surname>Griendling</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.freeradbiomed.2009.07.023</idno>
		<idno type="PMID">19628035</idno>
		<idno type="PMCID">PMC2763943</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2763943?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Free Radical Biology and Medicine</title>
		<title level="j" type="abbrev">Free Radical Biology and Medicine</title>
		<idno type="ISSN">0891-5849</idno>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1239" to="1253" />
			<date type="published" when="2009-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">cAbl Tyrosine Kinase Mediates Reactive Oxygen Species- and Caveolin-Dependent AT1 Receptor Signaling in Vascular Smooth Muscle: Role in Vascular Hypertrophy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ushio-Fukai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Zuo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Ikeda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Tojo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">A</forename><surname>Patrushev</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">W</forename><surname>Alexander</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.res.0000185322.46009.f5</idno>
		<idno type="PMID">16151024</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/01.RES.0000185322.46009.F5" />
	</analytic>
	<monogr>
		<title level="j">Circulation Research</title>
		<title level="j" type="abbrev">Circulation Research</title>
		<idno type="ISSN">0009-7330</idno>
		<idno type="ISSNe">1524-4571</idno>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="829" to="836" />
			<date type="published" when="2005-10-14" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Distinct Subcellular Localizations of Nox1 and Nox4 in Vascular Smooth Muscle Cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">L</forename><surname>Hilenski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Clempus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">T</forename><surname>Quinn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Lambeth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">K</forename><surname>Griendling</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.atv.0000112024.13727.2c</idno>
		<idno type="PMID">14670934</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/01.ATV.0000112024.13727.2c" />
	</analytic>
	<monogr>
		<title level="j">Arteriosclerosis, Thrombosis, and Vascular Biology</title>
		<title level="j" type="abbrev">Arteriosclerosis, Thrombosis, and Vascular Biology</title>
		<idno type="ISSN">1079-5642</idno>
		<idno type="ISSNe">1524-4636</idno>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="677" to="683" />
			<date type="published" when="2004-02-05" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Hydrogen peroxide generated extracellularly by receptor-ligand interaction facilitates cell signaling</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">J</forename><surname>Deyulia</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Carcamo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Borquez-Ojeda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Shelton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">W</forename><surname>Golde</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.0501154102</idno>
		<idno type="PMID">15795385</idno>
		<idno type="PMCID">PMC556007</idno>
		<ptr type="open-access" target="http://www.pnas.org/content/102/14/5044.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences</title>
		<title level="j" type="abbrev">Proceedings of the National Academy of Sciences</title>
		<idno type="ISSN">0027-8424</idno>
		<idno type="ISSNe">1091-6490</idno>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="5044" to="5049" />
			<date type="published" when="2005-03-28" />
			<publisher>Proceedings of the National Academy of Sciences</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Compartmental oxidation of thiol–disulphide redox couples during epidermal growth factor signalling</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patrick</forename><forename type="middle">J</forename><surname>Halvey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Walter</forename><forename type="middle">H</forename><surname>Watson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jason</forename><forename type="middle">M</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Mi</forename><surname>Go</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Afshin</forename><surname>Samali</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dean</forename><forename type="middle">P</forename><surname>Jones</surname></persName>
		</author>
		<idno type="DOI">10.1042/bj20041829</idno>
		<idno type="PMID">15647005</idno>
		<idno type="PMCID">PMC1134784</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc1134784?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Biochemical Journal</title>
		<title level="j" type="abbrev">Biochem. J.</title>
		<idno type="ISSN">0264-6021</idno>
		<idno type="ISSNe">1470-8728</idno>
		<imprint>
			<biblScope unit="volume">386</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="215" to="219" />
			<date type="published" when="2005-03-01" />
			<publisher>Portland Press Ltd.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">EGF receptor–ligand interaction generates extracellular hydrogen peroxide that inhibits EGFR-associated protein tyrosine phosphatases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Garrett</forename><forename type="middle">J</forename><surname>Deyulia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Juan</forename><forename type="middle">M</forename><surname>Cárcamo</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbrc.2005.06.056</idno>
		<idno type="PMID">15982634</idno>
	</analytic>
	<monogr>
		<title level="j">Biochemical and Biophysical Research Communications</title>
		<title level="j" type="abbrev">Biochemical and Biophysical Research Communications</title>
		<idno type="ISSN">0006-291X</idno>
		<imprint>
			<biblScope unit="volume">334</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="38" to="42" />
			<date type="published" when="2005-08" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Novel gp91 phox homologues in vascular smooth muscle cells : nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Lassègue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Sorescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Szö Cs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Akers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="888" to="894" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Characterization of phosphatidylinositol-specific phospholipase C from cultured vascular smooth muscle cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">K</forename><surname>Griendling</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">B</forename><surname>Taubman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Akers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mendlowitz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">W</forename><surname>Alexander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">266</biblScope>
			<biblScope unit="page" from="15498" to="15504" />
			<date type="published" when="1991" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Synthesis and cytotoxic evaluation of a series of resveratrol derivatives modified in C2 position</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xian-Feng</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ban-Feng</forename><surname>Ruan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiao-Ting</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chen</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hui-Ming</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hai-Liang</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ren-Xiang</forename><surname>Tan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejmech.2006.08.006</idno>
		<idno type="PMID">17000031</idno>
	</analytic>
	<monogr>
		<title level="j">European Journal of Medicinal Chemistry</title>
		<title level="j" type="abbrev">European Journal of Medicinal Chemistry</title>
		<idno type="ISSN">0223-5234</idno>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="263" to="267" />
			<date type="published" when="2007-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title level="m" type="main">Diphenyleneiodonium inhibits reduction of ironsulfur clusters in the mitochondrial NADH-ubiquinone oxidoreductase (Complex I)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Majander</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Finel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Wikströ M M</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">269</biblScope>
			<biblScope unit="page" from="21037" to="21042" />
			<date type="published" when="1994" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Specific Structural Determinants Are Responsible for the Antioxidant Activity and the Cell Cycle Effects of Resveratrol</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lucia</forename><forename type="middle">A</forename><surname>Stivala</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Monica</forename><surname>Savio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Federico</forename><surname>Carafoli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paola</forename><surname>Perucca</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Livia</forename><surname>Bianchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giovanni</forename><surname>Maga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Luca</forename><surname>Forti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ugo</forename><forename type="middle">M</forename><surname>Pagnoni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Angelo</forename><surname>Albini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ennio</forename><surname>Prosperi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vanio</forename><surname>Vannini</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.m101846200</idno>
		<idno type="PMID">11316812</idno>
		<ptr type="open-access" target="http://www.jbc.org/content/276/25/22586.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Biological Chemistry</title>
		<title level="j" type="abbrev">J. Biol. Chem.</title>
		<idno type="ISSN">0021-9258</idno>
		<idno type="ISSNe">1083-351X</idno>
		<imprint>
			<biblScope unit="volume">276</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="22586" to="22594" />
			<date type="published" when="2001-04-20" />
			<publisher>American Society for Biochemistry &amp; Molecular Biology (ASBMB)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">A theoretical antioxidant pharmacophore for resveratrol</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Auriekson</forename><forename type="middle">N</forename><surname>Queiroz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bruno</forename><forename type="middle">A Q</forename><surname>Gomes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Waldir</forename><forename type="middle">M</forename><surname>Moraes Jr.</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rosivaldo</forename><forename type="middle">S</forename><surname>Borges</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejmech.2008.09.023</idno>
		<idno type="PMID">18976835</idno>
	</analytic>
	<monogr>
		<title level="j">European Journal of Medicinal Chemistry</title>
		<title level="j" type="abbrev">European Journal of Medicinal Chemistry</title>
		<idno type="ISSN">0223-5234</idno>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1644" to="1649" />
			<date type="published" when="2009-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Inhibitory effect of resveratrol on angiotensin II-induced cardiomyocyte hypertrophy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tzu-Hurng</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ju-Chi</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Heng</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Neng-Lang</forename><surname>Shih</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yen-Ling</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Meng-Ting</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ching-Feng</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin-Jer</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00210-003-0849-6</idno>
		<idno type="PMID">14663554</idno>
		<idno type="ark">ark:/67375/VQC-34J16D5T-J</idno>
		<idno type="istexId">F273BD2A1042B6FED0D8B160E9D37CE704BDE393</idno>
	</analytic>
	<monogr>
		<title level="j">Naunyn-Schmiedeberg&apos;s Archives of Pharmacology</title>
		<title level="j" type="abbrev">Naunyn-Schmiedeberg&apos;s Archives of Pharmacology</title>
		<idno type="ISSN">0028-1298</idno>
		<idno type="ISSNe">1432-1912</idno>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="239" to="244" />
			<date type="published" when="2004-02-01" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Epidermal Growth Factor (EGF)-induced Generation of Hydrogen Peroxide</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yun</forename><forename type="middle">Soo</forename><surname>Bae</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sang</forename><forename type="middle">Won</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Min</forename><forename type="middle">Seok</forename><surname>Seo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ivan</forename><forename type="middle">C</forename><surname>Baines</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ephrem</forename><surname>Tekle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">Boon</forename><surname>Chock</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sue</forename><forename type="middle">Goo</forename><surname>Rhee</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.272.1.217</idno>
		<idno type="PMID">8995291</idno>
		<ptr type="open-access" target="http://www.jbc.org/content/272/1/217.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Biological Chemistry</title>
		<title level="j" type="abbrev">J. Biol. Chem.</title>
		<idno type="ISSN">0021-9258</idno>
		<idno type="ISSNe">1083-351X</idno>
		<imprint>
			<biblScope unit="volume">272</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="217" to="221" />
			<date type="published" when="1997-01-03" />
			<publisher>American Society for Biochemistry &amp; Molecular Biology (ASBMB)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Regulation of ROS signal transduction by NADPH oxidase 4 localization</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kai</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">T</forename><surname>Kirber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hui</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yu</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">F</forename><surname>Keaney</surname></persName>
		</author>
		<idno type="DOI">10.1083/jcb.200709049</idno>
		<idno type="PMID">18573911</idno>
		<idno type="PMCID">PMC2442210</idno>
		<ptr type="open-access" target="http://jcb.rupress.org/content/181/7/1129.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Cell Biology</title>
		<title level="j" type="abbrev">J Cell Biol</title>
		<idno type="ISSN">0021-9525</idno>
		<idno type="ISSNe">1540-8140</idno>
		<imprint>
			<biblScope unit="volume">181</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1129" to="1139" />
			<date type="published" when="2008-06-23" />
			<publisher>Rockefeller University Press</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Compartmentalization of Redox Signaling Through NADPH Oxidase–Derived ROS</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masuko</forename><surname>Ushio-Fukai</surname></persName>
		</author>
		<idno type="DOI">10.1089/ars.2008.2333</idno>
		<idno type="PMID">18999986</idno>
		<idno type="PMCID">PMC2842113</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2842113?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Antioxidants &amp; Redox Signaling</title>
		<title level="j" type="abbrev">Antioxidants &amp; Redox Signaling</title>
		<idno type="ISSN">1523-0864</idno>
		<idno type="ISSNe">1557-7716</idno>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1289" to="1299" />
			<date type="published" when="2009-06" />
			<publisher>Mary Ann Liebert Inc</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Resveratrol Improves Endothelial Function: Role of TNF and Vascular Oxidative Stress</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Ungvari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1161/atvbaha.109.187146</idno>
		<idno type="PMID">19478208</idno>
		<idno type="PMCID">PMC2761384</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.109.187146" />
	</analytic>
	<monogr>
		<title level="j">Arteriosclerosis, Thrombosis, and Vascular Biology</title>
		<title level="j" type="abbrev">Arteriosclerosis, Thrombosis, and Vascular Biology</title>
		<idno type="ISSN">1079-5642</idno>
		<idno type="ISSNe">1524-4636</idno>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1164" to="1171" />
			<date type="published" when="2009-05-28" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shu-Er</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ya-Ching</forename><surname>Hshu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong-Shyan</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jan-Kan</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1152/japplphysiol.00881.2006</idno>
		<idno type="PMID">17194732</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/6868/ef7820b70d2fa39d720c8c3e1026c2a948e7.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Applied Physiology</title>
		<title level="j" type="abbrev">Journal of Applied Physiology</title>
		<idno type="ISSN">8750-7587</idno>
		<idno type="ISSNe">1522-1601</idno>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1520" to="1527" />
			<date type="published" when="2007-04" />
			<publisher>American Physiological Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">The Possible Implication of trans-Resveratrol in the Cardioprotective Effects of Long-Term Moderate Wine Consumption</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Orallo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Camina</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Leiro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Gomez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Fernandez</surname></persName>
		</author>
		<idno type="DOI">10.1124/mol.61.2.294</idno>
		<idno type="PMID">11809853</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/bc9f/1ab6b8b39aa3220f131d4e83654c13ce1682.pdf" />
	</analytic>
	<monogr>
		<title level="j">Molecular Pharmacology</title>
		<idno type="ISSN">0026-895X</idno>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="294" to="302" />
			<date type="published" when="2002-02-01" />
			<publisher>American Society for Pharmacology &amp; Experimental Therapeutics (ASPET)</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
